The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|January 16, 2018
Charles River Laboratories Acquires KWS BioTest
Author(s)Pharmaceutical Technology Editors
The acquisition strengthens Charles River Laboratories’ capabilities in the oncology and immunology therapeutic areas.
Advertisement
On Jan. 11, 2018, Charles River Laboratories International, a contract research organization (CRO), announced its acquisition of KWS BioTest, a CRO specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases, for approximately £15 million (USD$21 million) in cash.
The acquisition provides additional and complementary tools, strengthening Charles River’s capabilities in the oncology and immunology therapeutics areas. In addition to the initial purchase price, the transaction includes a potential additional payment of up to £3 million (USD$4 million) based on future performance.
“The addition of KWS strategically expands Charles River’s existing discovery capabilities in the field of immunology, which is critical given the importance of new therapies which harness the human immune system. In addition to enhancing our position as the [single-source] provider for a broad portfolio of discovery services, KWS increases our ability to support clients’ early-stage drug research in critical therapeutic areas, and expands our geographic footprint in the United Kingdom,” said James C. Foster, chairman, president and CEO of Charles River, in a company press release.
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5